Targeted Therapies in Neuroblastoma: A History and a View to the Future
Cancers · 27.05.2026 · 18 (11) · 1742
DOI: 10.3390/cancers18111742 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancers, online erschienen am 27.05.2026. Verfasst von Nilay Shah. Beteiligte Einrichtung: Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH 43205, USA. Die Arbeit nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroblastomas remain a disproportionately morbid and mortal pediatric cancer. Representing 8% of all childhood cancer diagnoses, it still is the cause of 14% of cancer-related deaths in children despite the use of aggressive multimodal treatments with significant long-term sequelae. The development of targeted therapies for neuroblastoma has been and will continue to be the optimal approach to improve durable long-term survival in these patients while reducing the consequences of treatment. Here, I review the history of the development of targeted therapies for the treatment of neuroblastoma. I discuss the history of therapies that have been integrated into current treatment regimens, including isotretinoin, anti-GD2 antibodies and eflornithine. I review the history of candidate biologic targets in this malignancy as well as ongoing and future efforts to improve outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH 43205, USA.
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43210, USA.
ORCID-Profile: Nilay Shah
Zitieren
APA
Shah, N. (2026). Targeted Therapies in Neuroblastoma: A History and a View to the Future. Cancers, 18(11), 1742. https://doi.org/10.3390/cancers18111742
Vancouver
Shah N. Targeted Therapies in Neuroblastoma: A History and a View to the Future. Cancers. 2026;18(11):1742. doi:10.3390/cancers18111742
BibTeX
@article{Shah2026,
author = {Shah, Nilay},
title = {Targeted Therapies in Neuroblastoma: A History and a View to the Future},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1742},
doi = {10.3390/cancers18111742}
}
EUVIMED